Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

The high efficacy of therapeutic cancer vaccines in preclinical studies has yet to be fully achieved in clinical trials. Tumor immune suppression is a critical factor that hampers the desired antitumor effect. Here, we analyzed the combined effect of a cancer vaccine and the receptor tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Draghiciu, Oana, Nijman, Hans W, Hoogeboom, Baukje Nynke, Meijerhof, Tjarko, Daemen, Toos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404834/
https://www.ncbi.nlm.nih.gov/pubmed/25949902
http://dx.doi.org/10.4161/2162402X.2014.989764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404834/
https://www.ncbi.nlm.nih.gov/pubmed/25949902
http://dx.doi.org/10.4161/2162402X.2014.989764

Ejemplares similares